Pomalidomide-PEG3-CO2H

Background Introduction

Pomalidomide-PEG3-CO2H is a specialized E3 ligase ligand-linker conjugate designed for use in PROTAC (Proteolysis Targeting Chimera) technology. PROTACs are bifunctional molecules that harness the cellular ubiquitin-proteasome system to selectively degrade target proteins. This conjugate features pomalidomide, a cereblon (CRBN) E3 ligase recruiter, connected via a flexible PEG3 linker to a carboxylic acid functional group, making it an ideal intermediate for constructing novel PROTAC molecules.

Mechanism

Pomalidomide-PEG3-CO2H operates through a unique mechanism of action. The pomalidomide unit specifically binds to the CRBN component of the E3 ubiquitin ligase complex. The PEG3 linker provides optimal spatial arrangement and improved solubility, while the terminal carboxylic acid group facilitates coupling to various target protein ligands. When incorporated into a PROTAC, this conjugate enables the proximity-induced ubiquitination of the target protein, leading to its subsequent degradation by the proteasome.

Applications

Pomalidomide-PEG3-CO2H serves as a versatile building block in PROTAC research and development. It finds broad use in the synthesis of novel protein degraders for therapeutic, drug discovery, and chemical biology applications. By enabling the targeted degradation of disease-related proteins, PROTACs derived from this conjugate have potential in cancer research, neurodegenerative diseases, and other areas where protein modulation is crucial. Additionally, the conjugate's carboxylic group allows straightforward attachment to a diverse range of ligands, significantly accelerating the generation and optimization of custom PROTAC libraries.

• Polyethylene glycol (PEG3) linker improves aqueous solubility and bioavailability of PROTAC molecules.
• Carboxylic acid (CO2H) functional group enables efficient conjugation for CRBN E3 ligase-based PROTAC development.

Pomalidomide-PEG3-CO2H serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation by linking an E3 ligase ligand to a target protein ligand. This molecule enhances the selectivity and efficacy of PROTACs, paving the way for advanced research in protein homeostasis. The following provides a detailed description of this molecule.

Linker: The linker in Pomalidomide-PEG3-CO2H is a PEG3 unit, offering moderate flexibility and a length that ensures optimal spatial arrangement between the ligand and the target protein. Its non-cleavable nature provides stability, making it suitable for applications requiring prolonged action.

Ligand: The ligand portion of this molecule is based on pomalidomide, a thalidomide analog, known for its high affinity binding to the cereblon E3 ligase. Its structural characteristics include a glutarimide ring, which is crucial for effective recruitment of the E3 ligase.

Reactive Site: The reactive site is the terminal carboxylic acid group, which can couple with amine-containing target protein ligands. Recommended reaction types include amide bond formation through carbodiimide-mediated coupling, providing robust and stable linkages.

Recommended Target Protein Ligand: The compatible warhead for this molecule is typically an amine-reactive moiety, such as a primary amine. This configuration allows for the efficient formation of stable amide bonds, facilitating the degradation of target proteins. Its advantage lies in its ability to precisely modulate protein levels, offering valuable insights for experimental studies in drug discovery and development.